CClinicalTrials.gg
RecruitingNCT06413004Updated Jun 29, 2026

Brachyspira and Intestinal Allergy-like Immune Reactions in Patients With Irritable Bowel Syndrome (IBS)

An interventional study of Elimination and re-introduction of CLE or COLAP positive food item(s) in Irritable Bowel Syndrome and Food Sensitivity, sponsored by Magnus Simrén. Recruiting at 1 site in Sweden. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Magnus Simrén · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of this study is to define local immune responses in the GI tract to food antigens in IBS patients, with and without Brachyspira infection, using advanced imaging. We hypothesize that Brachyspira infection can cause IBS symptoms by inducing loss of oral tolerance to dietary antigens through development of food-specific intestinal immune reactions and subsequent development of visceral hypersensitivity.

During this study, the investigators will perform confocal laser endomiscroscopy (CLE) and/or colonoscopic antigen provocation test (COLAP) to test to which food items the participants react to. Furthermore, the investigators will perform rectal barostat examination and a sigmoidoscopy without laxatives. The investigators will collect biological samples and the participants will complete several questionnaires.

Read the detailed description

The aim of this study is to define local immune responses in the GI tract to food antigens in IBS patients with and without Brachyspira infection using advanced imaging. The investigators hypothesize that Brachyspira infection can cause IBS symptoms by inducing loss of oral tolerance to dietary antigens through development of food-specific intestinal immune reactions and subsequent development of visceral hypersensitivity.

Visit 1: inclusion, questionnaires, blood, rectal barostat examination Visit 2: questionnaires, blood, stool, diaries (food and stool), sigmoidoscopy (without laxantives) Allergologist visit (skin prick test and interpretation blood results) Visit 3A: stool, confocal laser endomicroscopy (CLE) OR colonoscopic antigen provocation test (COLAP) Visit 3B: facultative: in a subset of individuals, both CLE and COLAP will be performed (during separate visits)

Visit 4,5 and 6 only if the CLE or COLAP was positive for (at least) 1 food item

Visit 4: questionnaires and dietician-led instruction which food item to exclude (positive food item(s) during CLE/COLAP,), exclusion for 4 weeks. If both CLE and COLAP are positive, the diet will be COLAP-based.

Visit 5: questionnaires, stool diary, instructions re-introduction food item(s) Visit 6: questionnaires

QUESTIONNAIRES Baseline questionnaires; demographic, symptoms, symptom/medication/diet history, co-morbid medical conditions

IBS symptoms: IBS-Symptom Severity Scale (IBS-SSS) and Gastrointestinal Symptom Rating Scale (GSRS)-IBS

Psychological distress: Hospital Anxiety and Depression Scale (HADS), Patient Health Questionnaire (PHQ)-9 (both visit 1,4,5,6, generalized Anxiety Disorder 7-item scale (GAD-7)

Somatization: PHQ-15 for the number and severity of bodily symptoms.

Gastrointestinal specific anxiety: Visceral Sensitivity Index (VSI).

Sensitivity: Central Sensitization Inventory (CSI).

Food avoidance and restriction: (ARFID).

Stool habits and GI symptoms: 14-day GI symptom diary based on Bristol Stool Form Scale (BSFS).

Quality of life: IBS-Quality of Life (QOL).

Food intake: 4-days food diary, MealQ.

COLONOSCOPIC ALLERGEN PROVOCATION TEST, COLAP:

  • A local allergen provocation test, where dietary antigens (soy, wheat, (egg), gluten and milk), with saline and histamine as negative and positive controls, respectively are injected in the rectosigmoid mucosa (similar to skin prick test used for clinical allergy testing).
  • The intestinal reaction is determined visually ("wheal and flare reaction"), and biopsies are taken to characterize the immune response.
  • Bowel preparation before the investigation follows the normal clinical routine for colonoscopy, and i.v. sedatives and opioids are given during the investigation according to clinical routines at the endoscopy unit

CONFOCAL LASER ENDOMICROSCOPY, CLE, gastroscopy:

  • A probe-based endoscopic technique to study intestinal food reactions after iv injection of fluorescein.
  • Disruption of the small intestinal barrier in duodenum upon exposure to food antigens (soy, wheat, egg, gluten, milk, and control) can be determined.

VISCERAL SENSITIVITY:

•Rectal barostat sensitivity measurement: With the rectal barostat, the investigators can measure the rectal sensitivity. A balloon is inserted and inflated in the rectum in a controlled setting. The patient indicates when defined sensory thresholds are reached (first feeling of the balloon, urge to empty bowel, discomfort or pain). When the patient indicates discomfort or pain, or another reason to stop, the balloon inflation will be stopped.

SIGMOIDOSCOPY:

•Flexible sigmoidoscopy without bowel preparation, to interfere as little as possible with the normal gut microenvironment; fresh biopsies for specific analyses and biopsies stored for subsequent analyses.

BIOLOGICAL SAMPLES:

  • Blood - and plasma samples: Fasting blood samples are taken for routine blood tests (exclusion of organic diseases) and to determine the metabolic profile and genetic and immunological markers of relevance to intestinal function and nerve function. Serum samples will be analyzed with nuclear magnetic resonance (NMR) for metabolomic profile and microbial composition.
  • Fecal - and urine sample: The investigators will characterize the composition and function of the metabolome in detail via 16S analysis, metagenomics, transcriptomics, metabolomics, cell culture and cell count. Urine and fecal samples will also be analyzed with nuclear magnetic resonance (NMR) for metabolomic profile and microbial composition.
  • Biopsies (location based on the performed endoscopic examination): The investigators will conduct a detailed analysis of immune cells, proteins, nerve cells, and intestinal bacteria which will allow detailed mapping of intestinal function with respect to nerve, immune and barrier function.
02

Conditions studied

  • Irritable Bowel Syndrome
  • Food Sensitivity

Keywords

  • Irritable Bowel Syndrome
  • Food Sensitivity
  • Confocal Laser Endomicroscopy
  • Colonoscopic Antigen Provocation Test
03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with IBS diagnosis according to their treating physician (ROME IV).
  • Association between intake of food and GI symptoms.
  • Witnessed written informed consent prior to any study procedures.
  • Patients who are capable to understand the study and the questionnaires, and to comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

  • Patients with relevant concurrent organic GI disease (inflammatory bowel disease, abdominal cancer), or a major disease such as diabetes, uncontrolled thyroid disease, heart disease, kidney disease, liver disease, and active malignant disease (not those that were in remission at least 5 years).
  • Patients with a history of bowel surgery (not appendectomy or cholecystectomy) that affects GI motility.
  • Patients with systemic food allergy as evidenced by positive allergy tests (blood, prick test).
  • Clinical history of severe allergic reactions.
  • Patients with concurrent major confounding condition(s) based on the clinician's judgement, e.g. DOMINANT psychiatric disorder, vital depression, alcohol or substance abuse in the last 2 year.
  • Female patients who are pregnant or lactating (females of fertile age are requested to use a safe contraceptive) at the time of inclusion.
  • Patients who use or used new medications that affect the GI functioning within 1 month before the start of the study.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Other
    Positive food item during CLE or COLAP

    The food item(s) which were positive during CLE (fluorescein leakage and cell shedding) or COLAP (swelling).

    Other: Elimination and re-introduction of CLE or COLAP positive food item(s)

Interventions

  • OtherElimination and re-introduction of CLE or COLAP positive food item(s)

    Elimination (4 weeks) and re-introduction (4 weeks) of all CLE or COLAP positive food item(s)

05

What researchers measure

Primary outcomes

  1. IBS-SSS (Irritable Bowel Syndrom Severity Scoring System) after exclusion (proportion).

    the proportion of participants with an IBS-SSS reduction of ≥50 points, measured before (visit 4) and after (visit 5) exclusion of the CLE or COLAP positive food item(s) (= responders). IBS-SSS: higher IBS-SSS indicate more severe symptoms. Scores ranging 0-500.

    Time frame: 4 weeks after exclusion

Secondary outcomes

  1. IBS-SSS (Irritable Bowel Syndrom Severity Scoring System) after exclusion (absolute)

    IBS-SSS: absolute change of IBS-SSS, measured before (visit 4) and after (visit 5) EXCLUSION of the CLE or COLAP positive food item(s). Higher IBS-SSS indicate more severe symptoms. Scores ranging 0-500.

    Time frame: 4 weeks after exclusion

  2. IBS-SSS (Irritable Bowel Syndrom Severity Scoring System) after reintroduction (proportion)

    IBS-SSS: the proportion of participants with an IBS-SSS increase of ≥50 points, measured before (visit 5) and after (visit 6) the REINTRODUCTION of the CLE or COLAP positive food item(s): responders vs non-responders (as based on the primary outcome). Higher IBS-SSS indicate more severe symptoms. Scores ranging 0-500.

    Time frame: 4 weeks after reintroduction

  3. IBS-SSS (Irritable Bowel Syndrom Severity Scoring System) after reintroduction (absolute)

    IBS-SSS: the absolute change of IBS-SSS, measured before (visit 5) and after (visit 6) the REINTRODUCTION of the CLE or COLAP positive food item(s): total group and responders vs non-responders (as based on the primary outcome)

    Time frame: 4 weeks after reintroduction

  4. GSRS-IBS (the Gastrointestinal Symptom Rating Scale Irritable Bowel Syndrome version) after exclusion

    change of total and subscores before (visit 4) and after (visit 5) EXCLUSION of the CLE or COLAP positive food item(s). Total group and responders vs non-responders (as based on the primary outcome). Higher GSRS-IBS indicate more severe symptoms. After calculating of the average scores, those range 1-7.

    Time frame: 4 weeks after exclusion

  5. GSRS-IBS (the Gastrointestinal Symptom Rating Scale Irritable Bowel Syndrome version) after reintroduction

    change of total and subscores before (visit 5) and after (visit 6) REINTRODUCTION of the CLE or COLAP positive food item(s). Total group and responders vs non-responders (as based on the primary outcome). Higher GSRS-IBS indicate more severe symptoms. After calculating of the average scores, those range 1-7.

    Time frame: 4 weeks after reintroduction

  6. HAD (Hospital Anxiety and Depression scale) after exclusion

    change of total and subscores before (visit 4) and after (visit 5) EXCLUSION of the CLE or COLAP positive food item(s). Total group and responders vs non-responders (as based on the primary outcome). Higher HAD scores indicate more symtoms of anxiety and depression. Total score ranging 0-42 and the two subscores (anxiety and depression) ranging 0-21.

    Time frame: 4 weeks after exclusion

  7. HAD (Hospital Anxiety and Depression scale) after reintroduction

    change of total and subscores before (visit 5) and after (visit 6) REINTRODUCTION of the CLE or COLAP positive food item(s). Total group and responders vs non-responders (as based on the primary outcome). Higher HAD scores indicate more symtoms of anxiety and depression. Total score ranging 0-42 and the two subscores (anxiety and depression) ranging 0-21.

    Time frame: 4 weeks after reintroduction

  8. PHQ12 (the Patient Health Questionnaire - 12) after exclusion

    change of scores before (visit 4) and after (visit 5) EXCLUSION of the CLE or COLAP positive food item(s). Total group and responders vs non-responders (as based on the primary outcome). Higher PHQ12 scores indicate more bothersome non-GI somatic symptoms. Scores ranging 0-24, with a subanalysis excluding mentrual problems, leading to a range 0-22.

    Time frame: 4 weeks after exclusion

  9. PHQ12 (the Patient Health Questionnaire - 12) after reintroduction

    change of scores before (visit 5) and after (visit 6) REINTRODUCTION of the CLE or COLAP positive food item(s). Total group and responders vs non-responders (as based on the primary outcome). Higher PHQ12 scores indicate more bothersome non-GI somatic symptoms. Scores ranging 0-24, with a subanalysis excluding mentrual problems, leading to a range 0-22.

    Time frame: 4 weeks after reintroduction

06

Study locations

1 of 1 sites recruiting
  • Mag-tarmlab, Dept of Internal Medicine, Sahlgrenska University Hospital
    Gothenburg, 413 45, Sweden
    Recruiting
07

References and documents

Study documents

  • Study protocol · Apr 29, 2024

Documents are hosted by the registry — open the source record to download them.

08

Registry details

Key details

Study ID
NCT06413004
Lead sponsor
Magnus Simrén
Responsible party
Magnus Simrén (professor, Sahlgrenska University Hospital) — Sponsor-investigator
First posted
May 14, 2024
Start date
Aug 3, 2022
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jun 29, 2026

Study contacts

Magnus Simrén, MD PhD
Contact
magnus.simren@medicine.gu.se
0046313428107
MagTarmlab office
Contact
magtarmlab.su@vgregion.se
0046313428107

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion